Taiwan’s efforts to position itself as a major biotechnology hub received a further boost today with the opening of Merck KGaA’s dedicated technology training centre in Xizhi City, Taipei County.
Sartorius Stedim Biotech (SSB) and Bayer Technology Services (BTS) have signed an exclusive cooperation agreement for the manufacture and marketing of UVivatec products.
The European Parliament has voted in favour of incorporating the United Nations’ (UN) Globally Harmonised System (GHS) for chemical packaging into EU law.
in-PharmaTechnologist.com’s latest round up of products launched in the pharmaceutical manufacturing sector includes new offerings from Premier Pneumatics, GE Healthcare and WaterSep.
Agilent and Millipore have formed a collaboration to develop fully validated chromatin immunoprecipitation (ChIP) microarray kits that will improve productivity and streamline epigenetic analysis.
Abraxis has licensed rights to use ProMetic’s protein technology in the development of four new biopharmaceuticals that it hopes will generate around $600m (€422.5m) in US sales.
in-PharmaTechnologist.com’s latest round up of developments in contract manufacturing includes Therapure’s launch and facility expansions by Hollister-Stier, West and Dow.
UCB is moving forward with efforts to focus on CNS disorders and immunology and plans to cut around 2,000 jobs as part of its SHAPE restructuring program.
Applied Biosystems (ABI) has developed a sequencing-based tool for gene expression analysis that can detect even minute amounts of previously unknown RNA transcripts.
An increase in the sale of vaccines such as Quinvaxem and Epaxal, helped Dutch drugmaker Crucell reduce its loss some 56 per cent to €7.9m ($12.5m) in the second quarter.
in-PharmaTechnologist.com’s latest round up of products launched in the pharmaceutical manufacturing sector includes new offerings from Millipore, Sensor Products and Aspex.
Lonza is to co-develop and manufacture Novartis' biological pipeline as part of a long term strategic partnership that has been struck between the companies.
The PER.C6 cell culture-based antibody production platform has
achieved a new record yield of 27 grams of IgG antibody per litre,
bettering the 15 gram per litre mark that was reported earlier in
the year.
Invitrogen plans to cement its place as one of the world's largest
suppliers of analysis tools and reagents for the life science and
pharmaceutical industries by acquiring Applied Biosystems (ABI).
Sartorius Stedim Biotech has teamed up with Wuxi AppTec to help
companies remove some of the strain of carrying out viral clearance
testing, which for large biopharmaceutical companies can carry a
price tag of up to $1m a year.
The Bio Affinity Company (BAC) has been contracted to create a
purification method for the production of a recombinant protein,
the clotting agent factor VIIa, made in the milk of transgenic
animals.
Europe is tipped to witness the most significant worldwide gains in
biopharmaceutical manufacturing production capacity in the coming
years, despite an overall global decline in capacity utilisation by
the industry.
Agilent Technologies is expanding its nucleic acid active
pharmaceutical ingredient (API) manufacturing facility in Boulder,
Colorado, US, as the industry gravitates towards the
development of oligonucleotide-based drugs.
The opening of ORF Genetics' $1m production site for recombinant
proteins in Grindavik, Iceland, is yet another groundbreaking move
by this year's winner of the Icelandic Centre for Research's
innovation award.
The Bio Affinity Company (BAC) has introduced two new products for
scientists who need to purify hard-to-separate antibodies such as
immunogloblins A and M.
Two products aimed at enhancing the efficiency of process
development in biopharmaceutical manufacturing are the latest
offerings from GE Healthcare, the UK-based medical technology and
services company.
The use of disposable manufacturing equipment in pharmaceutical
production and greater need for containment equipment were
recurring themes at the Interphex show in Philadelphia last week,
and both were addressed by new equipment...
Syft Technologies of New Zealand released the latest generation of
Selected Ion Flow Tube-Mass Spectrometry (SIFT) instrumentation at
Pittcon 2008 for the analysis of very low levels of organic
compounds in air (detection limits as...
Pharmaceutical manufacturers, distributors and retailers alike have
welcomed a unanimous vote by the California State Board of Pharmacy
to delay for another two years the implementation of electronic
pedigree requirements for tracking...
Varian, Invitrogen, BMG Labtech and Hosokawa Micron have all
recently announced new product launches, detailing a selection of
tools and equipment to aid the scientist working in the laboratory
environment.
Bayer Healthcare is to deploy a new technique, developed by
Millipore, for genetically engineering cells to produce
pharmaceutically useful proteins that could both increase the yield
and accelerate drug production.
Novartis has lent impetus to the growing trend towards
philanthropic R&D in the pharmaceutical industry by opening a
new research institute in Siena, Italy "with a non-profit
mission to exclusively focus on the development...
Germany put in a strong showing as category winners were announced
for the fourth annual Facility of the Year Awards (FOYA)
recognising innovation in pharmaceutical manufacturing projects.
Artel has introduced a new feature for its Multichannel
Verification System (MVS), which includes an automation function
that allows for time savings and reducing human error.
Cellexus Biosystems, the UK company that designs, manufactures and
sells disposable cell growth technology for the biopharmaceutical
industry, is extending the rental plan offered on its CellMaker
Lite2 single-use bioreactor in response...
With the price of crude oil going up almost every day it is no
surprise that this has a knock-on effect to the price of raw
materials for the pharmaceutical and chemical industries. But DSM
and Roquette have developed a process that...
Separations expert Millipore is collaborating with Rohm and Haas
Company to develop new high-performance chromatography products for
use in biopharmaceutical manufacturing.
Two new techniques have been developed that could signal the end of
PCR (polymerase chain reaction) amplification for sequencing
applications and dramatically increase the efficiency of sample
preparation.
Netherlands-based DSM has invested an undisclosed sum in Danish
purification technology company Upfront Chromatography to boost its
protein separation business.
SolVin is to expand its polyvinylidene chloride (PVDC) latex
manufacturing site in Tavaux, France, in a bid to meet growing
demand for the packaging material.
ZS Genetics has signed up outside academic assistance to speed
up development of its 'revolutionary' microscopy-based genetic
analysis technology platform.
Industrial microbiology expert bioMerieux has acquired Australian
firm BTF, strengthening its quality control (QC) and manufacturing
quality assurance (QA) offerings to the pharmaceutical industry.
J&J has expressed its concern over patient safety as Novartis'
subsidiary Sandoz has received the green light from the European
Commission to launch the first epoetin alfa biosimilar on the EU
market.
US researchers have shown certain organic solvents can be used to
selectively extract therapeutic proteins from host bacteria,
avoiding the need for cell lysis and increasing product purity by a
factor of five.
Baxter Healthcare remains in murky waters in regard to its infusion
pumps after announcing yesterday it would be recalling an
additional 986 of its Colleague brand pumps.
Procter & Gamble (P&G) has announced its intention to
outsource the active pharmaceutical ingredient (API) R&D and
manufacturing work undertaken at one of its US factories, with
resultant closure of the site and job losses.
A European regulatory committee has recommended the approval of
three generic versions of Johnson & Johnson's (J&J) anaemia
blockbuster Eprex in what could lead to the market launch of new
"biosimilars" by the...
Roche has committed hundreds of millions of dollars to an
early-phase rheumatoid arthritis drug, a move that is indicative of
big pharma's increasing tendency to license earlier phase
compounds.